Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Propanc Biopharma Inc (PK) | PPCBD | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.0545 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.0545 | 0.0545 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 0.02 - 0.20 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.0545 | USD |
Propanc Biopharma Inc (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 225.48k | 4.14M | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Propanc Biopharma (PK) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/22/2024 | 11:12 | Edgar (US Regulatory) | Form 8-K - Current report |
| 4/10/2024 | 15:20 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/11/2024 | 14:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/20/2024 | 13:39 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 2/14/2024 | 13:47 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
| 12/15/2023 | 14:57 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/07/2023 | 15:18 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/14/2023 | 14:03 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 11/03/2023 | 15:05 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities |
| 10/30/2023 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/26/2023 | 15:42 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/06/2023 | 16:26 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PPCBD Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.19255 | 0.20 | 0.02 | 0.0639996 | 194,113 | -0.13805 | -71.70% |
| 3 Years | 0.19255 | 0.20 | 0.02 | 0.0639996 | 194,113 | -0.13805 | -71.70% |
| 5 Years | 1,120.00 | 6,490.00 | 0.02 | 370.82 | 85,526 | -1,119.95 | -100.00% |
Propanc Biopharma (PK) Description
| Propanc Biopharma, Inc. is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from solid tumors, such as pancreatic, ovarian and colorectal cancers. The Company's novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body's primary defense against cancer. |
